4.7 Article

A Thieno[2,3-d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D2 Receptor

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 62, 期 1, 页码 174-206

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.7b01565

关键词

-

资金

  1. National Health and Medical Research Council (NHMRC) [APP1049564]

向作者/读者索取更多资源

Recently, a novel negative allosteric modulator (NAM) of the D-2-like dopamine receptors 1 was identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural determinants of this allostery. We find that key structural moieties are important for functional affinity and negative cooperativity, while functionalization of the thienopyrimidine at the 5- and 6-positions results in analogues with divergent cooperativity profiles. Successive compound iterations have yielded analogues exhibiting a 10-fold improvement in functional affinity, as well as enhanced negative cooperativity with dopamine affinity and efficacy. Furthermore, our study reveals a fragment-like core that maintains low mu M affinity and robust negative cooperativity with markedly improved ligand efficiency.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

Schizophrenia-associated SAP97 mutations increase glutamatergic synapse strength in the dentate gyrus and impair contextual episodic memory in rats

Yuni Kay, Linda Tsan, Elizabeth A. Davis, Chen Tian, Lea Decarie-Spain, Anastasiia Sadybekov, Anna N. Pushkin, Vsevolod Katritch, Scott E. Kanoski, Bruce E. Herring

Summary: Mutations in the putative glutamatergic synapse scaffolding protein SAP97 can enhance glutamatergic synapse strength in the dentate gyrus, impairing contextual episodic memory in rats.

NATURE COMMUNICATIONS (2022)

Article Cardiac & Cardiovascular Systems

Eosinophils protect pressure overload- and β-adrenoreceptor agonist-induced cardiac hypertrophy

Chongzhe Yang, Jie Li, Zhiyong Deng, Songyuan Luo, Jing Liu, Wenqian Fang, Feng Liu, Tianxiao Liu, Xian Zhang, Yuanyuan Zhang, Zhaojie Meng, Shuya Zhang, Jianfang Luo, Conglin Liu, Dafeng Yang, Lijun Liu, Galina K. Sukhova, Anastasiia Sadybekov, Vsevolod Katritch, Peter Libby, Jing Wang, Junli Guo, Guo-Ping Shi

Summary: This study explored the role of blood eosinophil counts and eosinophil cationic protein (ECP) levels in cardiac hypertrophy. It revealed positive correlations between blood eosinophil counts and left ventricular mass in humans. Further experiments in mice showed that eosinophil deficiency exacerbated cardiac hypertrophy and dysfunction. The study also demonstrated that repopulation of eosinophils from wild-type mice improved cardiac hypertrophy. Mechanistic studies revealed that eosinophil expression of IL4, IL13, and mEar1 were essential in controlling cardiomyocyte hypertrophy and death, as well as fibroblast TGF-beta signaling and fibrotic protein synthesis. The use of human cardiac cells yielded similar results. The study suggests a cardioprotective role for eosinophils and ECP in cardiac hypertrophy and highlights the therapeutic potential of ECPs in cardiovascular disease.

CARDIOVASCULAR RESEARCH (2023)

Article Chemistry, Medicinal

Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H1 Receptor

Zhi Yuan Kok, Leigh A. Stoddart, Sarah J. Mistry, Tamara A. M. Mocking, Henry F. Vischer, Rob Leurs, Stephen J. Hill, Shailesh N. Mistry, Barrie Kellam

Summary: This study reports a series of high-affinity H1R fluorescent ligands, which overcome the limitations of linker SAR by incorporating a BODIPY 630/650-based fluorophore, and successfully visualizes HA at a concentration of 10 nM using confocal microscopy.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Biochemistry & Molecular Biology

Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs

Michael J. Cunningham, Hailey A. Bock, Inis C. Serrano, Benjamin Bechand, D. J. Vidyadhara, Emma M. Bonniwell, David Lankri, Priscilla Duggan, Antonina L. Nazarova, Andrew B. Cao, Maggie M. Calkins, Prashant Khirsariya, Christopher Hwu, Vsevolod Katritch, Sreeganga S. Chandra, John D. McCorvy, Dalibor Sames

Summary: Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that has been tested in humans, showing therapeutic effects such as remission of psychotic symptoms and improved cognition. It acts as a serotonin 5-HT2 receptor agonist with modest selectivity over 5-HT1 receptors. Compared to its hallucinogenic analog, Ariadne exhibits lower signaling potency and efficacy in multiple signaling pathways. It has considerable therapeutic potential across psychiatric and neurological indications.

ACS CHEMICAL NEUROSCIENCE (2023)

Article Multidisciplinary Sciences

Structure-based design of bitopic ligands for the mu-opioid receptor

Abdelfattah Faouzi, Haoqing Wang, Saheem A. Zaidi, Jeffrey F. DiBerto, Tao Che, Qianhui Qu, Michael J. Robertson, Manish K. Madasu, Amal El Daibani, Balazs R. Varga, Tiffany Zhang, Claudia Ruiz, Shan Liu, Jin Xu, Kevin Appourchaux, Samuel T. Slocum, Shainnel O. Eans, Michael D. Cameron, Ream Al-Hasani, Ying Xian Pan, Bryan L. Roth, Jay P. McLaughlin, Georgios Skiniotis, Vsevolod Katritch, Brian K. Kobilka, Susruta Majumdar

Summary: Researchers have developed a new approach to design safer therapeutic agents by targeting a conserved sodium ion-binding site in mu-opioid receptors. Cryo-electron microscopy structures revealed the key interactions between the ligands and the binding site, leading to the development of potent ligands with reduced adverse effects. This study highlights the potential of targeting the sodium ion-binding site for the design of safer analgesics and suggests that engagement of this site can control the efficacy and selectivity profiles of G-protein-coupled receptors.

NATURE (2023)

Article Biochemistry & Molecular Biology

Structural insights into angiotensin receptor signaling modulation by balanced and biased agonists

Dongqi Zhang, Yongfeng Liu, Saheem A. Zaidi, Lingyi Xu, Yuting Zhan, Anqi Chen, Jiangtao Guo, Xi-Ping Huang, Bryan L. Roth, Vsevolod Katritch, Vadim Cherezov, Haitao Zhang

Summary: The cryo-EM structure of human AT(1)R complexed with Sar(1)-AngII and G(q) protein reveals the molecular mechanisms of AT(1)R signaling modulation and biased signaling induced by mutations in the major hydrogen bond network. These findings have implications for drug discovery in cardiovascular diseases.

EMBO JOURNAL (2023)

Article Chemistry, Medicinal

Small-Molecule Fluorescent Ligands for the CXCR4 Chemokine Receptor

Sebastian Dekkers, Birgit Caspar, Joelle Goulding, Nicholas D. Kindon, Laura E. Kilpatrick, Leigh A. Stoddart, Stephen J. Briddon, Barrie Kellam, Stephen J. Hill, Michael J. Stocks

Summary: In this study, fluorescent probes based on previously reported small-molecule antagonists were designed and synthesized using classic medicinal chemistry approaches to investigate the pharmacology and cellular distribution of the CXCR4 receptor. Three distinct chemical classes of fluorescent probes were developed and shown to specifically bind to the CXCR4 receptor in a fluorescence-based NanoBRET binding assay (pKD ranging 6.6-7.1). These probes were also used in competition binding experiments and confocal microscopy to further explore the pharmacology and cellular distribution of CXCR4.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Review Multidisciplinary Sciences

Computational approaches streamlining drug discovery

Anastasiia V. Sadybekov, Vsevolod Katritch

Summary: Computer-aided drug discovery has experienced a significant shift towards computational technologies for efficient ligand screening. This shift is driven by the availability of vast ligand data, abundant computing capacities, and virtual libraries of drug-like small molecules. Recent advances in deep learning predictions of ligand properties and target activities, as well as structure-based virtual screening, have the potential to reshape the drug discovery and development process. The rapid identification of diverse, potent, target-selective, and drug-like ligands to protein targets can democratize the drug discovery process, enabling cost-effective development of safer and more effective treatments.

NATURE (2023)

Article Multidisciplinary Sciences

Molecular mechanism of biased signaling at the kappa opioid receptor

Amal El Daibani, Joseph M. M. Paggi, Kuglae Kim, Yianni D. D. Laloudakis, Petr D. Popov, Sarah M. M. Bernhard, Brian E. E. Krumm, Reid H. J. Olsen, Jeffrey Diberto, F. Ivy Carroll, Vsevolod Katritch, Bernhard Wuensch, Ron O. O. Dror, Tao Che

Summary: Using structural determination, molecular dynamics simulations, and functional assays, the researchers identified molecular determinants of KOR signaling bias. They determined the crystal structure of KOR bound to the G protein-biased agonist nalfurafine and identified an arrestin-biased KOR agonist, WMS-X600. Through simulations and mutagenesis validation, they explained how agonists achieve biased signaling at KOR.

NATURE COMMUNICATIONS (2023)

Article Multidisciplinary Sciences

Structural details of a Class B GPCR-arrestin complex revealed by genetically encoded crosslinkers in living cells

Yasmin Aydin, Thore Bottke, Jordy Homing Lam, Stefan Ernicke, Anna Fortmann, Maik Tretbar, Barbara Zarzycka, Vsevolod V. Gurevich, Vsevolod Katritch, Irene Coin

Summary: Understanding the molecular basis of arrestin-mediated regulation of GPCRs is crucial for deciphering signaling mechanisms. However, structural studies are challenging due to the dynamic nature of GPCR-arrestin complexes. In this study, the interaction between arrestin-2 and PTH1R was dissected using crosslinking amino acids in live cells. The integrative approach revealed the structure, dynamics, and flexible regions of the PTH1R-arrestin2 complex.

NATURE COMMUNICATIONS (2023)

Article Pharmacology & Pharmacy

Assessment of the potential of novel and classical opioids to induce respiratory depression in mice

Rob Hill, Julie Sanchez, Laura Lemel, Mirjana Antonijevic, Yselkla Hosking, Shailesh N. Mistry, Andrew C. Kruegel, Jonathan A. Javitch, J. Robert Lane, Meritxell Canals

Summary: This study evaluated the effects of three novel opioids on respiratory depression and analgesia, and compared these measurements with their in vitro efficacy. The results showed that these opioids can induce respiratory depression and analgesia at certain doses, but there are differences in potency and duration of effect among the novel opioids.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Chemistry, Medicinal

Design, Synthesis, and Application of Fluorescent Ligands Targeting the Intracellular Allosteric Binding Site of the CXC Chemokine Receptor 2

Bianca Maria Casella, James P. P. Farmer, Desislava N. N. Nesheva, Huw E. L. Williams, Steven J. J. Charlton, Nicholas D. D. Holliday, Charles A. A. Laughton, Shailesh N. N. Mistry

Summary: Inhibition of CXCR2 is a potential strategy for the treatment of pulmonary diseases and cancers. This study reports the design and synthesis of fluorescent NAMs that selectively bind to CXCR2, enabling the measurement and evaluation of their pharmacological properties. These NAMs can be used as alternative compounds for targeting these receptors.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Hematology

Characterizing the binding of glycoprotein VI with nanobody 35 reveals a novel monomeric structure of glycoprotein VI where the conformation of D1+D2 is independent of dimerization

Foteini-Nafsika Damaskinaki, Natalie J. Jooss, Eleyna M. Martin, Joanne C. Clark, Mark R. Thomas, Natalie S. Poulter, Jonas Emsley, Barrie Kellam, Steve P. Watson, Alexandre Slater

Summary: This study investigates the binding sites of three high-affinity nanobodies, Nb2, Nb21, and Nb35, on the platelet-signaling receptor GPVI. The researchers found that all three nanobodies can bind to the D1 domain of GPVI and inhibit collagen-induced GPVI signaling. They also identified common target residues, Arg46, Tyr47, and Ala57, on GPVI for these nanobodies. Additionally, the study negates the idea that GPVI dimerization induces a conformational change required for ligand binding.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Meeting Abstract Pharmacology & Pharmacy

A fluorescent G protein mimetic peptide probe for high-throughput characterisation of intracellular allosteric modulator binding and GPCR activation

James Farmer, Nicholas Holliday, Shailesh Mistry, Charles Laughton

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Multidisciplinary Sciences

Structure-based design of bitopic ligands for the μ-opioid receptor

Abdelfattah Faouzi, Haoqing Wang, Saheem A. Zaidi, Jeffrey F. DiBerto, Tao Che, Qianhui Qu, Michael J. Robertson, Manish K. Madasu, Amal El Daibani, Balazs R. Varga, Tiffany Zhang, Claudia Ruiz, Shan Liu, Jin Xu, Kevin Appourchaux, Samuel T. Slocum, Shainnel O. Eans, Michael D. Cameron, Ream Al-Hasani, Ying Xian Pan, Bryan L. Roth, Jay P. McLaughlin, Georgios Skiniotis, Vsevolod Katritch, Brian K. Kobilka, Susruta Majumdar

Summary: This study presents an approach to design safer analgesics by targeting a conserved sodium ion-binding site in mu-opioid receptor (mu OR) using bitopic fentanyl derivatives. Cryo-electron microscopy structures reveal key interactions between the ligands and mu OR, demonstrating nanomolar potency, high efficacy, and reduced adverse effects. This study suggests the potential of the mu OR sodium ion-binding site as a target for the design of safer analgesics.

NATURE (2023)

暂无数据